Although activators of NRF2 are opening new perspectives in the treatment of different renal pathologies, underlying its protective role in kidney tissue, its aberrant hyperactivation is becoming a central driver of progression of different cancer types, such as renal cell carcinoma. Here, NFE2L2 is linked to hereditary clear cell renal cell carcinoma.